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ABSTRACT 
Objective: Olmesartan is a BCS class II anti-hypertensive drug with limitations of low aqueous solubility and bioavailability. Present work was 
designed to use complexation as an approach to explore the ability of modified cyclodextrin such as sulphobutyl ether
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7 β-cyclodextrin (SBE7β-CD) 
to develop an inclusion complex with poorly soluble olmesartan medoxomil (OLM) for improving its dissolution rate and relative bioavailability. 
Methods: Inclusion complexes were prepared by different techniques of physical mixing, kneading and lyophilisation. Prepared complexes were 
characterized by differential scanning calorimetry (DSC), powder x-ray diffractometry (X-RPD), proton nuclear magnetic spectroscopy (1H NMR) 
and fourier transforms infrared spectroscopy (FT-IR). Molecular interaction and encapsulation in an inclusion complex at the molecular level were 
considered using docking chemistry.  
Results: Phase solubility analysis revealed 13 fold increase in aqueous solubility with stability constant Ks=249 M−1at 1:1 stoichiometry of 
complexation. DSC and XPRD confirmed the reduction of crystallinity in complexes with improved solubility. 1H NMR and FT-IR studies depicted the 
interaction among functional groups with varied hydrogen shifts confirmed by molecular modelling. Dissolution studies of complexes have shown 
an improved dissolution rate when compared to plain OLM. Pharmacokinetic profile of OLM/SBE7β-CD has shown a significant enhancement in the 
relative bioavailability. 
Conclusion: SBE7
Keywords: Complexation, Molecular modelling, Relative bioavailability, Olmesartan medoxomil, Sulphobutyl ether
β-CD may be successfully used as a carrier for the oral administration of OLM with enhanced bioavailability subjected to future 
scale up. 
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Olmesartan medoxomil (OLM) chemically (5-methyl-(2-Oxo-1,3-
dioxol-4-yl)methyl-4-(1-hydroxy-1-methyl ethyl)-2-propyl-1-[2′(1H) -
tetrazole-5yl)1,1 ′biphenyl-(4-yl) methyl]-1H-imidazole-5-carboxylate) 
is an ester prodrug that is quickly and fully hydrolyzed to the active 
metabolite olmesartan by both arylesterase and albumin during 
gastrointestinal absorption [1] as shown in fig. 1a. 
 
 
Fig. 1a: Conversion of OLM to its active metabolite OL 
 
OLM is a weak base (pKa =4.3) with high molecular weight of 558.59 
[1, 2] highly lipophilic and classified as class II drug according to the 
biopharmaceutical classification system (BCS) where its dissolution 
is the rate-limiting step for absorption. The drug has an oral 
bioavailability of about 29% only [3, 4]. It is an angiotensin II 
receptor blocker that selectively blocks the binding of angiotensin II 
to the AT1 receptor in vascular smooth muscle. It was approved by 
the US Food and Drug Administration (FDA) in 2002 for the 
treatment of hypertension either singly or in combination [5].  
Various approaches such as self-micro emulsifying drug delivery 
systems (SMEDDS) and lipid-based formulations have been 
investigated for enhancing the oral bioavailability of OLM [6]. Recent 
reports highlighted the cardioprotective and the nephro protective 
effects of OLM [7-9]. Considering the potential of protective effects 
shown in recent studies and dissolution related problems associated 
with OLM utility a strategy utilizing cyclodextrin complexation for 
improving the solubility and relative bioavailability of OLM has been 
explored for the first time. Of all the cyclodextrin derivatives SBE 7
10
β-
CD was proved to be a very good solubilizer for the drugs with high 
molecular weight [ ]. Aqueous solubility of SBE7β-CD (70 g/100 ml 
at 25oC) is appreciably higher than β-cyclodextrin (1.85 g/100 ml at 
25o 11C) [ ]. SBE7
Furthermore, SBE
β-CD is a chemically modified β-CD commercially 
available as Captisol® and is cyclic hydrophilic oligosaccharide with 
the negative charge in aqueous media as shown in fig. 2.  
7β-CD does not exhibit the nephrotoxicity and 
cytotoxic effects on intestinal epithelial Caco-2 cells like β-
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cyclodextrin [12]. Thus selected complexing agent was considered to 
be very safe for oral administration [3, 13] and also found to be 
superior solubilizer compared to β-CD because of its greater 
electronic interactions with drug [14, 15]. Considering the above 
favourable aspects in terms of solubility, electronic interactions and 
safety modified cyclodextrin was chosen for further studies. 
 
 
Fig. 2: Structure of sulfobutyl ether7β-cyclodextrin 
 
In the present investigation, we studied the ability of selected 
cyclodextrin to form an inclusion complex with OLM to enhance the 
solubility, dissolution rate and relative bioavailability of OLM. The 
OLM/SBE7β-CD complex formation was confirmed and characterized 
by various techniques like Differential Scanning Calorimetry (DSC), 
X-Ray Powder Diffraction (X-RPD), Nuclear Magnetic Resonance 
Spectroscopy (1H-NMR) and Fourier Transform Infra Red 
Spectroscopy (FT-IR). Furthermore, we have also studied different 
modes of interactions. The superior efficacy of the OLM/SBE7β-CD 
complexes with respect to in vitro dissolution rate and in vivo oral 
bioavailability has been successfully demonstrated in comparisons 
to pure OLM. 
MATERIALS AND METHODS 
Materials 
OLM form B (Benicar) was kindly supplied by Daiichi Sankyo 
research Centre in India, Gurgaon. Captisol® (Sulphobutyl Ether7β-
Cyclodextrin) was purchased from CyDex pharmaceuticals (USA). 
Milli-Q water was used throughout the study and solvents methanol, 
acetonitrile (J. T. Baker, USA) used were of analytical grade. 
Animals 
Young adult male Wistar rats weighing 200-220 g were procured 
from the animal house Ranbaxy (Gurgaon, India). Rats were housed 
in properly ventilated cages at room temperature (24±2o
A phase solubility study was carried out in triplicates in distilled 
water at 25ºC to investigate the effect of SBE7β-CD on the solubility 
of OLM [
C) and 40-
60% relative humidity while on a regular 12 h light-dark cycle. The 
animals were acclimatized for a period of three days prior to the 
start of experimentation. The animal protocol to carry out the in vivo 
study was reviewed and permitted by the Institutional Animal Ethics 
Committee, Ranbaxy-RCI (approval no: DS2012/011) and their 
guidelines were followed throughout the study. 
Preliminary phase solubility studies 
16]. An excess amount of drug was added to 2 ml aqueous 
solution containing different molar concentrations of SBE7β-CD 
(average molecular weight 2,163) in increasing amounts from 0-80 
mM and kept on shaker water bath (Gas-col® test tube shaker, USA) 
for 72 h at 25 °C. After equilibrium, the solutions were centrifuged 
(eppendorf centrifuge) at 3100 rpm for 15 min and filtered using 
0.45 µm, 25 mm PTFE (poly tetra fluoro ethylene) filter and diluted 
suitably with distilled water to determine the concentration of OLM 
using waters acquity ultra-pressure liquid chromatography (UPLC) 
system with a photodiode array detector at 256 nm. 
Chromatographic analysis was done using sunniest C-18HT column 
(2 µm, 50×2.1 mm) with a gradient flow program of two mobile 
phases consisting of water: acetonitrile (95:5, v/v) with 0.05 % 
formic acid (A) and acetonitrile with 0.05 % formic acid (B) at a flow 
rate of 0.7 ml/min. The solubility phase profile of OLM was plotted 
for the concentration (mM) of drug and complexing agent and 
apparent stability constant Ks of the complex was determined from 
the graph using equation given by Higuchi and Connors (1965). 
(1) 
Where, the slope was obtained from the graph and So was the 
equilibrium solubility of OLM in water without cyclodextrin. 
Jobs plot of continuous variation 
Jobs plot of continuous variation method [17] was used to determine 
the stoichiometry of the binding event between drug and 
complexing agents. Stock solutions of 100 μM OLM and SBE7β-CD in 
distilled water were prepared. The samples were prepared by 
mixing different volumes of OLM and complexing agent in such a 
way that a mole fraction of OLM and CD were in the range of 0-1. The 
peak area difference between the samples containing drug with and 
without SBE7β-CD were measured using UPLC. Complex 
stoichiometry was determined from the plot of the peak area 
difference versus the mole fraction of SBE7β-CD.  
Preparation of OLM/SBE7β-CD physical mixture and inclusion 
complexes 
The inclusion complexes of OLM with SBE7β-CD in 1:1 ratio were 
prepared by three different methods 
Physical mixture (PM) 
The physical mixture was prepared by simple mixing of equimolar 
quantities of OLM and SBE7β-CD in a mortar pestle for 10 min. The 
prepared mixture was passed through BSS 120 sieve mesh for uniform 
size and kept in the desiccator until further analysis performed. 
Kneading method 
Equimolar quantities of OLM and SBE7β-CD were added separately 
to 10 ml of methanol and mixed thoroughly. Prepared drug solution 
was slowly added to methanolic SBE7β-CD under trituration and the 
mixture was further kneaded for 3–4 h until evaporation of 
methanol. During the process of kneading few drops of water was 
added to maintain appropriate consistency of the mass. The 
resultant mass was dried in an oven (Shel Lab Oven, USA) at 45o
Equimolar quantities of OLM and SBE7β-CD were added to 10 mlof 
methanol and water respectively. Both solutions were mixed, and 
the resultant solution was frozen in a deep freezer (New Brunswick 
Scientific, Germany) at-70 
C for 
48 h. The dried kneaded product (KP) was finally grounded and 
stored as discussed for physical mixture [18]. 
Lyophilisation method 
oC for about 1 h. The frozen mixture was 
further freeze-dried in the freeze dryer (Heto dry winner with rotary 
vane pump, Germany) at-110 °C to-120 o
20
C under vacuum for 8 h. The 
resultant lyophilization product (LP) was sieved as discussed earlier 
and stored accordingly [19, ].  
Characterization of the inclusion complexes of OLM in solid state 
Differential scanning calorimetry (DSC) 
The thermal properties of OLM, SBE7β-CD, PM and inclusion 
complexes (KP and LP) were investigated using a DSC (Shimadzu 
QA-100 Thermal Analyzer) calibrated with indium. 3 mg of 
respective sample (plain OLM, SBE7β-CD, PM and inclusion 
complexes) were accurately weighed into aluminium pans, sealed 
and scanned at a rate of 10 oC/min between 40 _ 250 o
The crystalline or amorphous state of complexes was studied by X-
RPD. The X-RPD patterns of plain OLM, SBE7β-CD, PM and inclusion 
C in nitrogen 
atmosphere applied at 40 ml/min.  
X-Ray powder diffraction analysis (X-RPD) 
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complexes (KP and LP) were recorded on an analytical Xpert 
powder x-ray diffractometer (Philips P) using Ni-filtered, CuKα 
radiation wavelength of 1.5405 Ao was used as x-ray source over the 
diffraction angle range (2θ) of 5–40 ° at 1 °/min with voltage of 40 
kV and 25 mA current.  





H-NMR spectra of plain OLM, PM, inclusion complexes (KP and 
LP)and SBE7β-CDwere performed in DMSO and plain heavy water 
(D2O) respectively on a Bruker ultra shield 400 MHz NMR [ ]. The 
spectra were processed using topspin 2.0 software. 
Fourier transforms infrared spectrophotometry (FT-IR) 
Drug excipients interactions were analysed by FT-IR studies (Perkin-
Elmer Model 1600). Spectra of OLM, SBE7β-CD, PM and inclusion 
complexes (KP and LP) containing an equivalent amount of 2.0 mg 
OLM were recorded in the range of 4000–400 cm−1
Molecular docking studies of OLM with sulfobutyl ether7 β-
cyclodextrin [SBE7β-CD] were carried using GLIDE module of 
Schrödinger suite 2013. Co-ordinates for sulfobutylether7 β-
cyclodextrin were generated by adding sulfobutyl ether group at 
7
 using KBr discs.  
Molecular modelling studies 
th
22
position of β-cyclodextrin. Further, it has been prepared for 
docking by adding hydrogen and minimized. The 3D structure of 
OLM was sketched and minimized by OPLS-2005 molecular 
mechanics force field using Ligprep module of Schrödinger. A total of 
10 conformations were generated. Grid was generated around 
sulfobutyl ether 7β-cyclodextrin with x: 19.7004; y: -8.0605; z: 
0.2067 co-ordinates. Glide XP docking was performed. Molecular 
docking of OLM with β-cyclodextrin was also performed to compare 
the binding affinity with that of SBE7β-CD [ ]. 
In vitro dissolution profile of complexes 
The in vitro dissolution test of prepared complexes was performed in 
0.1 M PBS buffer pH 6.8 (900 ml) using USP Type II apparatus (DISTEK 
dissolution system 4300) maintained at 37±0.5 °C, operated at the 
speed of 50±2 rpm. Plain OLM, PM and inclusion complexes (all 
equivalent to 20 mg of OLM) were weighed accurately and placed in 
the dissolution medium. Aliquots of 2 mlwere withdrawn at fixed time 
intervals from the dissolution medium and replaced with an 
equivalent amount of fresh media. The withdrawn samples were 
filtered through a 0.22 µm nylon filter and the amount of OLM released 
in the dissolution medium was determined by defining the peak area 
of the suitably diluted aliquot using UPLC. 
Determination of dissolution parameters  
Dissolution data was analyzed using Dissolution Efficiency (DE15) at 
15 min and Mean dissolution time (MDT) [23]. DE is the area under 
the dissolution curve up to a certain time 't' expressed as a 
percentage of the area of the rectangle described by 100% 
dissolution at the same time. Representative equation is as follows:  
DE = ∫ Υ×
t
0 dt
∫ Υt0 100  t
 (2) 
It is preferable to choose a time interval corresponding to 70–90% 
dissolution unless one wishes to compare an early part of the 
dissolution curve. In the current study t1=0 and t2=60 min were 
chosen. Mean dissolution time is the arithmetic mean value of any 
dissolution data and is described as below:  




Where j is the sample number, n is the number of dissolution 
sampling times, t is the time at the midpoint between t and t-
1(calculated with (t+t–1)/2) and ΔMj is the additional amount of 
drug dissolved between t and t-1. 
In vivo relative bioavailability study  
In vivo relative bioavailability was carried out on 6-week-old male wistar 
rats weighing 200-220 gm. Plain OLM, PM and inclusion complexes were 
administered as a suspension using 0.5% methylcellulose via oral gavage 
at 5 mg/kg as OLM. Blood samples of about 0.3 mlwere collected using 
heparinized tubes at predetermined time intervals 0.25, 0.5, 1, 2, 4, 6, 8, 
10, 12 and 24 h and centrifuged at 12,000 rpm for 10 min. Plasma 
samples were stored at -20 o
The bioanalytical method was developed using UPLC to determine the 
concentrations of OLM in rat plasma. A 100 µl aliquot of plasma was 
transferred into a glass tube. A measured volume of 200 µl 1M HCl and 5 
mlof extraction solvent tertiary butyl methyl ether (TBME) was added to 
this mixture. OLM was extracted from plasma after vortex mixing and 
centrifugation at 3000 rpm for 10 min. The supernatant was transferred 
into a glass tube and evaporated at 40 




C under a gentle stream of 
nitrogen gas. The residue was reconstituted with 100 µl of methanol and 
was injected into the UPLC system. The plasma concentrations were 
determined by using calibration equation obtained by least-squares 
linear regression over the range 50-2000 ng/ml in plasma. The limit of 
detection (LOD), the lower limit of quantification (LOQ), accuracy and 
precision were determined as per the limits according to FDA bio-
analytical guidelines [ ]. 
RESULTS AND DISCUSSION 
Binary systems were prepared by different techniques such as PM, 
KM and LM.  
Phase solubility studies 
The effect of modified cyclodextrin on the aqueous solubility of a 
drug was evaluated using solubility phase method. The phase 
solubility diagram for OLM in sulphobutyl cyclodextrin complex is 
represented in Fig.3a. The aqueous solubility of the drug increased 
linearly as a function of SBE7β-CD concentration with a correlation 
coefficient (r2) of 0.998. Phase diagram can be assigned as AL type 
according to Higuchi and Connors method.
Complex formation occurs at 1:1 stoichiometry ratio since slope was 
lower than 0.002. An increase in solubility of the drug from 
0.0073±0.0003 mM (without cyclodextrin) to 0.0950±0.0022 (in 80 
mM cyclodextrin) was obtained. The apparent stability constant (KS) of 





linear plot of the phase-solubility diagram [ ]. It was observed that 
SBE7β-CD yielded a 13 fold increase in the aqueous solubility of OLM.  
 
 
Fig. 3a: Phase solubility studies for olmesartan medoxomil 
(OLM) in the presence of sulphobutyl ether7 β-cyclodextrin 
(SBE7β-CD) 
 
Jobs plot of continuous variation 
The solubility of OLM with modified cyclodextrin was determined by 
continuous variation method. fig. 3b displays job plot of differences 
in peak area of the drug as a function of mole fraction of complexing 
agent. The jobs plot of OLM with SBE7β-CD exhibit a max at R= 0.5 
with high relative symmetry indicating the complex possess a peak 
corresponding to 1:1 stoichiometry (table 1). 
Sampathi et al. 




Fig. 3b: Jobs plot of OLM/SBE7β-CD 
Table 1: Jobs plot of continuous variation 
S. No. Mole fraction 
of SBE7 β-CD 
Difference in the peak area of 
complexed and uncomplexed OLM 
1 0 295 
2 0.2 782 
3 0.4 958 
4 0.5 1254 
5 0.6 992 
6 0.8 875 
7 1 312 
 
Characterization of the inclusion complexes 
Differential scanning calorimetry (DSC) 
The DSC thermograms of OLM, PM, KP and LP are shown in fig. 4a-
4e. The DSC of plain OLM and SBE7β-CD has shown a sharp 
endothermic peak at 183.1 oC and 87.4o
 
C corresponding to the 





Fig. 4: DSC thermogram of a) olmesartan (OLM) b) sulphobutyl ether7β-cyclodextrin c) physical mixture (PM), d) kneaded product (KP) 
and e) lyophilised product (LP) 
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The peak at SBE7β-CD was due to the liberation of crystal water. A 
characteristic well recognizable peak of the drug corresponding to 
its melting point was slightly reduced in the physical mixtures of 
drug (endothermic peak at 182.2oC) but in other inclusion 
complexes, there was a slight increase in melting points of drug 
(185oC and 184.3oC) respectively.  
The PM and inclusion complexes retained endothermic peaks of 
both SBE7β-CD and OLM indicated that there was no chemical 
interaction, but the heat of fusion (J/gm), intensity and height of the 
endotherm was reduced re-presentated that complexation may 
result in reduced crystallization of OLM. Similarly, the endothermic 
peak of SBE7β-CD at 87.5 oC was shifted to 108.6oC, 185.0oC and 85.6 
o
The physical state of the drug in inclusion complex was verified 
by another thermal technique X-RPD pattern along with DSC for 
confirmation. Diffraction patterns for drug and complexes LP are 
shown in fig. 5a-5e. The characteristic peaks of OLM were at ∼9
C for PM (partial complex), KP and LP respectively indicating the 
formation of stable complexes. 
X-ray powder diffraction (X-RPD) 
o, 
12o, 14o, 16o, 18o, 19o and 21.2±0.2o on 2θ confirmed crystalline 
nature of drug while the absence of sharpness in peaks of 
cyclodextrins clearly revealed amorphous halo nature. Crystallinity 
was determined by comparing some representative peak height 
[OLM peak at 22.12o
(4) 
 (2θ)] in the diffraction pattern of the binary 
systems with those of a reference. The relative degree of crystallinity 
(RDC) was defined according to the equation:  
Where Isam is the peak height of sample and Iref is the peak height at 
the same angle for the reference with the highest intensity [26, 27]. 
The RDC values of corresponding binary systems of OLM/SBE7β-CD 
were shown in table 2. All sharp peaks mainly at ∼22 ° on 2θ were 
seen with a reduced intensity to a great extent of ∼2000 in PM, ∼1500 
in KP and ∼1000 in LP and were diffused which indicated decreased 
crystalline nature of OLM in all cases. Most importantly the significant 
peaks of OLM at 12 ° (∼2200), 19 ° (∼3500) and 24 °(∼4,050) on 2θ 
were absent in the X-RPD of the KP and LP inclusion complexes. The 
results of the X-RPD studies indicated that drug had formed an 
inclusion complex with a simultaneous reduction in the crystallinity in 





Fig. 5: XRD pattern of a) olmesartan (OLM) b) sulphobutyl Ether7β-cyclodextrin c) physical mixture (PM), d) kneaded product (KP) and e) 
lyophilised product (LP) 
 
Table 2: Peak intensities and RDC values for OLM: SBE 7 β-CD complexes 
Parameters OLM PM KP LP 
2θ 6658 2035 1243 903 
RDC 1 0.305 0.186693 0.135626 
Sampathi et al. 
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Nuclear magnetic resonance studies (1H-NMR) 
1H-NMR can provide evidence of the inclusion of drug molecule 
within the cavity of SBE7β-CD. In general, if a guest or drug molecule 
is located within CD cavity inner hydrogen and OH groups are 
shielded by the drug while outer groups are unaffected by complex 
formation. The interaction among groups can be seen by chemical 
shifts in drug molecule. The 1H-NMR spectra of OLM and its 
complexes were recorded to study closely the interaction of the drug 
with cyclodextrin. The 1H-NMR spectra of OLM and SBE7β-CD are 
shown in fig. 6a-6b. The chemical shifts observed for OLM and 
SBE7β-CD were given below:  1
SBE7β-CD 
H-NMR (CDCl3) δ: 7.81(dd, 1H), 7.52-
7.6(m, 3H), 7.05(d, 2H), 6.85(d, 2H), 5.42(s, 1H),5.05(s, 1H), 2.58(t, 
3H), 2.07(s, 3H), 1.57-1.59(m, 2H), 1.47(s, 6H), 0.89(t,3H). 
1H-NMR (D2O): δ ppm 3.82 (H5 proton), 3.75(H6 proton), 
3.66 (H1′ proton), 3.54 (H2 proton), 2.89 (H4′ proton), and 1.72 (H3′ 
H2′ protons) SBE7β-CD 1H-NMR (CD3OD/D2O): δ ppm 5.04 (H1 
proton), 4.03(H3 proton), and 3.57 (H4 proton). fig. 6c-6e: Shows 
the 1
 





Fig. 6: NMR spectra of a) olmesartan medoxomil OLM, b) sulphobutyl Ether7β-cyclodextrin (SBE7β-CD), c) physical mixture (OLM/SBE7β-
CD), d) kneaded product and e) lyophilised product 
 
The NMR spectra show characteristic protons of OLM and the 
protons in the cavity of SBE7β-CD are distinct and can be used as 
probes to monitor the interaction between OLM and SBE7β-CD. It 
is evident in fig. 6c-6e that there were eminent changes in the 
prototype of the NMR signals of the protons of aromatic benzyl 
groups of OLM for both the PM and inclusion complexes. In 
addition changes in the pattern of the NMR signals of the cavity 
protons of SBE7β-CD hydroxyl groups were observed both for the 
PM and the inclusion complexes. These changes clearly indicated 
some form of interaction between SBE7β-CD OH groups and OLM 
aromatic groups in both the PM as well as the inclusion 
complexes. However, due to difficulties in extracting accurate 
changes in the chemical shifts elaborate characteristics of the 
interaction cannot be inferred and the discussed interactions 
were further supported by the results from molecular modelling 
studies. 
1
The principal peak hydrogen stretching of the NH group, C-H of 
aromatic rings and aliphatic groups for plain OLM at 3291.16 cm
H-NMR results showed that the principal chemical shifts (δ) in plain 
OLM were at 7 ppm for aromatic hydrogens and for the plain SBE7β-
CD were at 4 ppm for either groups. These chemical shifts were 
absent in complexes indicating strong interactions.  
Fourier transforms infrared spectroscopy (FT-IR) 
The FT-IR spectra of plain OLM, SBE7β-CD, PM, KP and LP were 
shown in fig. 7a-7e.  
-1, 
3000-3100 cm-1 and 2850-2960 cm-1 respectively got enclosed with 
the broad alcoholic OH stretch peak at 3430 cm-1 of SBE7β-CD in the 
physical mixture and inclusion complexes. The principal peak for 
C=C bond stretching of aromatic groups at 1500-1600 cm-1 range of 
plain OLM was absent in PM and inclusion complexes indicating a 
strong interaction or bonding between OLM and SBE7β-CD. The 
hydrogen of CH3 group and aromatic C=O group stretching’s in plain 
OLM, PM and inclusion complexes formed an umbrella deformation 
at 1380 cm-1 and 1832 cm-1respectively were absent in plain SBE7β-
CD indicating that those groups were freely exposed. Along with this 
the specific C=O group stretching at 1707 cm-1 of plain OLM was 
seen in PM and other inclusion complexes indicating that part was 
not entrapped by SBE7β-CD. But the C-O and C-N is stretching at 
1260-1000 and 1340-1020 cm-1 range of plain OLM was not exposed 
Sampathi et al. 
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in PM and other inclusion complexes. These results suggested that 
both the complexes and the PM possess a strong interaction between 
SBE7β-CD and OLM being more conspicuous in the complex. The 
enclosure of IR absorption bands of the hydrogen of OH, an aromatic 
ring and aliphatic groups, the C=C stretching of the aromatic group 
in OLM by the OH group of SBE7β-CD were signposts of interaction 
between OLM and SBE7β-CD. In the PM the interaction between OLM 
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Fig. 7: FT-IR spectra of (a) olmesartan medoxomil OLM, (b) sulphobutyl ether7β-cyclodextrin (SBE7β-CD), (c) physical mixture 
(OLM/SBE7β-CD), (d) kneaded product and (e) lyophilised product 
 
Molecular modelling studies 
In SBE7β-CD randomly the OH groups in cyclodextrin were replaced 
with the sulphobutyl ether groups. As the actual substitution pattern 
and the configurations have not been revealed by the manufacturer 
in the present investigation three possible isomers of SBE7β-CD 
were employed in the molecular modelling studies.  
The results of the docking studies of OLM with the three different SBE7β-
CD isomers have been shown in fig. 8a-8c. It was evident that in three 
isomers that OLM was partially embedded in the SBE7β-CD cavity ie. the 
aromatic rings lie within the SBE7β-CD cavity. This clearly explained the 
change in the pattern of the IR and NMR signals of aromatic protons in 
the OLM/SBE7β-CD complex. It was evident from fig. 8c that in third 
isomer OLM interacted with the sulphobutyl either arms of SBE7β-CD.  
In molecular docking, the intermolecular hydrogen bond between 
the tetrazole group of olmesartan and the OH of the glucose unit of 
SBE7β-CD was shown in fig. 8a. In contrast, the complex with 
isomer 2 shows hydrogen bonding occurred between the NH of the 
tetrazole group of OLM and the 3-OH group of the glucose unit of 
SBE7β-CD.  
In isomer 1 hydrogen bond between carboxylic-OH groups and OH 
group of glucopyranose units of cyclodextrin was present, whereas 
in isomer 3 hydrogen bonds between imidazole ring of OLM and 
OH group of glucopyranose units of cyclodextrin was observed. 
After the molecular modelling studies of three isomers, we have 
noticed that the hydrophobic part of OLM was enclosed by the 
hydrophobic cavity of SBE7β-CD which ultimately enhanced the 
solubility of OLM. 
 
  
Fig. 8a: 3D structures of the complex between the olmesartan medoxomil and sulphobutyl ether7β-cyclodextrin (SBE7β-CD) isomer 1 
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Fig. 8b: 3D structures of the complex between the olmesartan medoxomil and sulphobutyl ether7β-cyclodextrin (SBE7β-CD) isomer 2 
 
  
Fig. 8c: 3D structures of the complex between the olmesartan medoxomil and sulphobutyl ether7β-cyclodextrin (SBE7β-CD) isomer 3  
 
In vitro dissolution study 
The dissolution profiles of the plain drug, physical mixture and 
inclusion complexes were presented as the mean percentage release 
of drug with respect to time as shown in fig. 9a. The percentage 
release after 120 min for both inclusion complexes KP and LP were 
shown 99.98 % and 99.78% respectively than PM and OLM with 
66.36% and 57.63% respectively. 
 
e  
Fig. 9a: In vitro dissolution profiles of pure olmesartan 
medoxomil, PM and inclusion complexes 
 
Dissolution profiles were compared with dissolution efficiency at 15 
min (DE15) and mean dissolution times (MDT) as given in table 3. 
The significant enhancement of the dissolution efficiency that 
occurred with kneaded and lyophilized products has been attributed 
to an increase of OLM solubility upon complexation in the solid state 
due to the reduction of crystalline nature. MDT was considerably 
lower for the KP and LP indicating a faster dissolution rate for 
complexes compared to plain OLM. The in vitro results have shown 
that drug dissolution rates of complexes were evidently higher than 
that of the plain drug which can be attributed to enhanced drug 
solubility achieved by the complexation technique. This was also 




Fig. 9b: Mean plasma concentration-time profiles of olmesartan 
medoxomil, PM and inclusion complexes after oral administration 
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In vivo relative bioavailability in rats 
The relative bioavailability (BA) study in rats was conducted to 
evaluate absorption of inclusion complexes compared with the plain 
drug. Plasma OL levels (metabolite) were measured to assess the 
pharmacokinetic parameters because OL levels reflect OLM 
pharmacokinetics [28]. The mean plasma OL levels were higher for 
inclusion complexes than the plain OLM suspension as shown in fig. 
9b. It has been reported that cyclodextrin/drug complexes yield 
improvement in oral bioavailability and therapeutic efficacy [29-32]. 
In view of this the OLM/SBE7β-CD complex is expected to show 
higher therapeutic efficacy or enhanced relative oral bioavailability. 
The pharmacokinetics parameters for OLM such as maximum 
plasma concentration (Cmax), plasma half-life (t1/2) and area under 
the concentration-time curve (AUC) were listed in table 4. 
 
Table 3: Mean dissolution time and dissolution efficiency of plain OLM, PM, KP and LP 
S. No. Sample Mean dissolution time (in min) Dissolution Efficiency 
1 OLM plain drug 31 50.56% 
2 Physical mixture 27 55.43% 
3 Kneaded product 18.4 63.96% 
4 Lyophilized product 19.2 63.51% 
 
Table 4: Pharmacokinetic parameters of pure OLM, KP and LP (5.0 mg/kg oral dose) in rats 
Parameters OLM KP LP 
AUC 0-24h (ng. h/ml) 4041.4±159 7480.9±292 8481.8±331 
AUC 0-∞ (ng. h/ml) 4293.1±311 7906.3±329 8950.7±372 
Cmax (ng/ml) 617.3±43 997.5±217 1145.2±221 
T1/2 (h) 2.97±0.31 3.48±0.17 3.09±0.14 
Relative % Bio-availability* - 185.8 209.9 
*% Relative Bio-availability = AUCOLM/AUCcomplex 
 
The relative BA of OLM in KP and LP was 185.2, 185.8 and 209.9% 
respectively. The AUC (0–24 h) and AUC (0–∞) of OLM were only 4041 and 
4293 ng. h/ml respectively because slower dissolution of OLM 
particles in suspension is the rate-limiting step for intestinal 
absorption. The AUC and Cmax of inclusion complexes were increased 
which implied enhancement of solubilization of drug in inclusion 
complexes by improving oral bioavailability by overcoming the 
dissolution step. The relative bioavailability, Cmax and AUC of the 
inclusion complexes were significantly higher than those of the plain 
drug suspension due to enhanced solubility. 
CONCLUSION 
The inclusion complexes of OLM were successfully prepared by 
employing modified sulphobeta cyclodextrin though different 
techniques physical mixing, kneading and freeze-drying. Phase 
solubility profile of inclusion complexes provides evidence of 
improved solubility with 13 fold increase as compare to a plain drug 
with complexation stoichiometry as 1:1 confirmed by jobs plot. DSC 
and XRD showed a reduction in crystallinity and no interaction 
among components. NMR predicted different hydrogen shift during 
complexation. Complexation was further supported through FTIR. 
The inclusion complex exhibited significantly higher in vitro 
dissolution profile as compared with plain OLM drug. The in vivo 
pharmacokinetic parameters showed enhancement of relative 
bioavailability of inclusion complexes with good correlation. Hence, 
the inclusion complexes of OLM with SBE7β-CD have more feasibility 
for further development as an efficient oral delivery system with 
enhanced bioavailability at a low cost. 
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